Emma Walmsley, GSK CEO (GSK Investor)
February 1, 2023 07:43 AM EST
R&D

GSK drops celi­ac drug, an­ti-bac­te­r­i­al vac­cine in lat­est pipeline sweep

Amber Tong

On a con­tin­ued mis­sion to set a high bar for its R&D group — which now gears heav­i­ly to­ward vac­cines and spe­cial­ty med­i­cines — GSK has swept …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times